CDLX vs MGNI

For growth investors, Magnite, Inc.

(MGNI) is the stronger pick with 6. 9% revenue growth year-over-year, versus -16. 2% for Cardlytics, Inc. (CDLX). Magnite, Inc. (MGNI) offers the better valuation at 14. 1x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Magnite, Inc. (MGNI) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Magnite, Inc.

(MGNI) delivered a total return of -58. 5%, compared to -99. 2% for Cardlytics, Inc. (CDLX). Over 10 years, the gap is even starker: MGNI returned -4. 7% versus CDLX's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Magnite, Inc.

(MGNI) is the lower-risk stock at 1. 63β versus Cardlytics, Inc. 's 3. 18β — meaning CDLX is approximately 95% more volatile than MGNI relative to the S&P 500.

By revenue growth (latest reported year), Magnite, Inc.

(MGNI) is pulling ahead at 6. 9% versus -16. 2% for Cardlytics, Inc. (CDLX). On earnings-per-share growth, the picture is similar: Magnite, Inc. grew EPS 493. 8% year-over-year, compared to 50. 1% for Cardlytics, Inc.. Over a 3-year CAGR, MGNI leads at 7. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Magnite, Inc.

(MGNI) is the more profitable company, earning 20. 3% net margin versus -44. 4% for Cardlytics, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGNI leads at 13. 7% versus -20. 2% for CDLX. At the gross margin level — before operating expenses — MGNI leads at 62. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Magnite, Inc.

(MGNI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cardlytics, Inc. (CDLX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGNI: -4. 7%, CDLX: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Communication Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CDLX is a small-cap quality compounder stock; MGNI is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.